eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | cystoid macular dystrophy |
| Comorbidity | |retinal vein occlusion |
| Sentences | 118 |
| PubMedID- 20417567 | Objective: to evaluate the safety and efficacy of dexamethasone intravitreal implant (dex implant; ozurdex, allergan, inc., irvine, ca) compared with sham in eyes with vision loss due to macular edema (me) associated with branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo). |
| PubMedID- 24876761 | Treatment of systemic hypertension is important for improvement of macular edema associated with retinal vein occlusion. |
| PubMedID- 21598607 | [medium-term effects of intravitreal bevacizumab for macular edema associated with central retinal vein occlusion]. |
| PubMedID- 21744123 | Lamellar macular hole formation in chronic cystoid macular edema associated with retinal vein occlusion. |
| PubMedID- 24492507 | [20] the authors recommend the use of a single injection of ranibizumab followed by a single session of laser photocoagulation to treat macular edema associated with branch retinal vein occlusion. |
| PubMedID- 25644536 | Purpose: to determine whether the highly reflective vertical lines seen in spectral-domain optical coherence tomographic (sd oct) images, which we have termed track lines, after resolution of macular edema associated with branch retinal vein occlusion are related to the integrity of the photoreceptors. |
| PubMedID- 21726846 | Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. |
| PubMedID- 25526099 | Other reasons included diabetic macular edema, cystoid macular edema because of retinal vein occlusions, cytomegalovirus retinitis, and severe uveitis. |
| PubMedID- 22358585 | Prospective multicenter study of visual outcomes following three different treatments for macular edema associated with branch retinal vein occlusion: a study by the japanese brvo study group. |
| PubMedID- 22991926 | Retinal function and morphology in central retinal vein occlusion with macular edema. |
| PubMedID- 25902119 | Background: macular edema resulting from central retinal vein occlusion is effectively treated with anti-vascular endothelial growth factor injections. |
| PubMedID- 21478810 | Conclusion: these results suggest that a rebound of macular edema in eyes with branch retinal vein occlusion was more likely to occur when the intravitreal bevacizumab therapy is initiated before the macular edema reaches the maximum level. |
| PubMedID- 25576994 | Therapies for macular edema associated with central retinal vein occlusion: a report by the american academy of ophthalmology. |
| PubMedID- 23225839 | Triamcinolone intravitreal injection and intraocular pressure in macular edema associated with retinal vein occlusion. |
| PubMedID- 25390716 | Conclusion: ozurdex may be effective in reducing macular edema because of a branch retinal vein occlusion in eyes refractory to multiple other treatments. |
| PubMedID- 23379834 | Background: it is unclear how retinal ischemia influences the changes of visual acuity, macular sensitivity, macular thickness, and macular volume after the performance of pars plana vitrectomy (ppv) for macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 24311895 | Ranibizumab is now fda approved for the treatment of age-related macular degeneration as well as macular edema associated with retinal vein occlusion. |
| PubMedID- 24526927 | The ozurdex dexamethasone-sustained delivery implant has been approved by the united states food and drug administration (fda) for the treatment of macular edema associated with retinal vein occlusion (rvo) and for noninfectious posterior uveitis. |
| PubMedID- 23510041 | Background and objective: to evaluate the influence of serous retinal detachment (srd) on the outcome of pars plana vitrectomy (ppv) for macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 23483492 | Treatment of macular edema associated with retinal vein occlusion using sustained-release dexamethasone implants in a clinical setting. |
| PubMedID- 24778755 | Branch retinal vein occlusion with sectoral cystoid macular edema in toxoplasmic chorioretinitis. |
| PubMedID- 21191716 | Purpose: to study prognostic factors for visual acuity (va) after intravitreal bevacizumab injection (ivb) for macular edema (me) associated with retinal vein occlusion (rvo), by evaluating the correlation between the final va and va at baseline and at 1, 3, and 6 months after the initial ivb. |
| PubMedID- 20801424 | Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 25634982 | Purpose: the association between aqueous humor levels of various growth/inflammatory factors or cytokines and the severity of macular edema was investigated in patients with central retinal vein occlusion (crvo). |
| PubMedID- 24967199 | Aqueous levels of erythropoietin in acute retinal vein occlusion with macular edema. |
| PubMedID- 26501219 | The primary treatment against macular edema with retinal vein occlusion (rvo) has changed from observation in central rvo (crvo) and laser photocoagulation in branch rvo (brvo) to administration of intravitreal agents based on anti-vascular endothelial growth factor (vegf) or anti-inflammatory strategies. |
| PubMedID- 21383939 | Clinical studies indicate that this dexamethasone implant is a promising new treatment option for patients with persistent macular edema resulting from retinal vein occlusion, diabetic retinopathy, and uveitis or irvine-gass syndrome. |
| PubMedID- 22105941 | To investigate whether vitreous fluid levels of vascular endothelial growth factor (vegf), pigment epithelium-derived factor (pedf), and soluble intercellular adhesion molecule 1 (sicam-1) influence visual prognosis and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 23972086 | Aqueous soluble vascular endothelial growth factor receptor-2 in macular edema with branch retinal vein occlusion. |
| PubMedID- 23539479 | The influence of retinal ischemia on changes of visual acuity, macular sensitivity, macular thickness, and macular volume is unclear after pars plana vitrectomy (ppv) for macular edema with branch retinal vein occlusion (brvo). |
| PubMedID- 21805173 | Association of electroretinogram and morphological findings in branch retinal vein occlusion with macular edema. |
| PubMedID- 20453544 | The outcome of vitrectomy for macular edema was examined in patients with central retinal vein occlusion (crvo), as well as whether vascular endothelial growth factor (vegf) and interleukin-6 (il-6) levels in vitreous fluid influence the visual prognosis and macular edema. |
| PubMedID- 24741610 | It was approved by the fda for the treatment of neovascular amd, macular edema associated with retinal vein occlusion, and since 2012, it is approved for the treatment of dme [23]. |
| PubMedID- 23046435 | Changes of inflammatory factors after intravitreal triamcinolone acetonide for macular edema with central retinal vein occlusion. |
| PubMedID- 21211297 | Objective: to study the correlation of visual acuity and photoreceptor in eyes with persistent cystoid macular edema associated with branch retinal vein occlusion (brvo). |
| PubMedID- 25657578 | Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 20531142 | Conclusion: individualized repeated intravitreal injections of ranibizumab showed promising short-term results in visual acuity improvement and decrease in cft in patients with macular edema associated with branch retinal vein occlusion. |
| PubMedID- 22095093 | Purpose: to study the correlation of retinal sensitivity with both morphologic changes in the macula and status of retinal capillary perfusion, after resolution of the macular edema associated with retinal vein occlusion (rvo). |
| PubMedID- 23842103 | Purpose: to evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 24528934 | Purpose: to test a combination of dexamethasone intravitreal implant with macular grid laser for macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 23044946 | Management of macular edema associated with retinal vein occlusion. |
| PubMedID- 26335912 | Purpose: our aim was to investigate predictive factors associated with efficacy and recurrence after intravitreal bevacizumab (ivb) therapy for macular edema (me) in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 24447389 | Additional sources of data included clinical study reports for ranibizumab [27-31], the dexamethasone ivt manufacturer’s submission to the national institute for health and clinical excellence (nice) for dexamethasone ivt and the evidence review group response [32,33] and results of the global evaluation of implantable dexamethasone in retinal vein occlusion with macular edema (geneva) studies reported within the clinicaltrials.gov records [34,35]. |
| PubMedID- 21784203 | Intravitreal injection of autologous plasmin enzyme for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 22988344 | Ozurdex received fda approval in june 2009 for the treatment of macular edema associated with retinal vein occlusion, and in september 2010, it became the second fda-approved therapeutic agent for the treatment of noninfectious posterior uveitis.in a 26-week, multicenter, double-masked, randomized clinical study in which 229 patients were randomized in a 1 : 1 : 1 ratio receiving 0.70 mg ozurdex (n = 77), 0.35 mg ozurdex (n = 76), or sham injection (n = 76). |
| PubMedID- 21845032 | It may be most appropriate for motivated, phakic, or pseudophakic patients with simple branch retinal vein occlusions associated with macular edema and significant hemorrhage, who are unwilling or unable to tolerate more frequent intravitreal injections required for anti-vegf therapy, or for patients who have demonstrated intolerance or recalcitrant edema following anti-vegf therapy. |
| PubMedID- 22474425 | The dexamethasone drug delivery system (dds) [ozurdex, allergan, irvine, california] is a biodegradable, sustained-release device approved by the us fda for the treatment of macular edema associated with retinal vein occlusion and noninfectious posterior segment uveitis. |
| PubMedID- 24439442 | Presence of foveal bulge in optical coherence tomographic images in eyes with macular edema associated with branch retinal vein occlusion. |
| PubMedID- 22392532 | It is an fda-approved intravitreal therapy for the treatment of age-related macular degeneration [70] and macular edema associated with retinal vein occlusion [71]. |
| PubMedID- 22044337 | Rapid resolution of macular edema associated with central retinal vein occlusion using ranibizumab after failure with multiple bevacizumab injections. |